Biosig Technologies (NASDAQ:STEX) CIO Sells $25,000.50 in Stock

Biosig Technologies, Inc. (NASDAQ:STEX) CIO Mitchell Young Williams sold 23,810 shares of Biosig Technologies stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $1.05, for a total value of $25,000.50. Following the sale, the executive directly owned 3,013,838 shares in the company, valued at $3,164,529.90. This trade represents a 0.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mitchell Young Williams also recently made the following trade(s):

• On Friday, May 1st, Mitchell Young Williams sold 263,863 shares of Biosig Technologies stock. The shares were sold at an average price of $0.79, for a total value of $208,451.77.

Biosig Technologies Price Performance

Shares of STEX opened at $1.18 on Friday. The company’s 50 day simple moving average is $1.09. The company has a market cap of $214.52 million, a P/E ratio of -0.12 and a beta of 1.85. Biosig Technologies, Inc. has a 12-month low of $0.70 and a 12-month high of $14.11.

Biosig Technologies (NASDAQ:STEX) last issued its earnings results on Thursday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Needham & Company LLC decreased their target price on Biosig Technologies from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, May 21st. Wall Street Zen cut Biosig Technologies from a “hold” rating to a “strong sell” rating in a report on Sunday, April 5th. Finally, Weiss Ratings upgraded Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.00.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.